The EMA at 20: CAT chair on where all the advanced therapies are, and Holoclar, the bright light of stem cell therapy
This article was originally published in SRA
Advanced therapy medicinal products (ATMPs) were never going to be easy products for regulators to deal with, which is why the European Medicines Agency's Committee for Advanced Therapy Medicinal Products (CAT) was set up in 2009. So far, the applications have not exactly flooded in, but this is likely to change over the next few years, says Paula Salmikangas, chair of the CAT. She talks to Francesca Bruce about the pitfalls of developing an ATMP and why Europe's first stem cell therapy, Holoclar, was a beacon of light for the sector.